Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

other Versions

You are currently viewing an earlier version of this article (May 20, 2021).
View the most recent version of this article

Original research

Metronomic oral cyclophosphamide in relapsed ovarian cancer

Online download statistics by month:

Online download statistics by month: May 2021 to May 2023

	Abstract	Full	Pdf
May 2021	35	13	12
Jun 2021	37	13	7
Jul 2021	36	17	12
Aug 2021	9	4	7
Sep 2021	8	7	6
Oct 2021	280	12	5
Nov 2021	169	4	3
Dec 2021	323	4	3
Jan 2022	356	8	3
Feb 2022	155	3	5
Mar 2022	242	4	3
Apr 2022	225	1	0
May 2022	282	3	1
Jun 2022	264	10	1
Jul 2022	297	14	3
Aug 2022	290	11	4
Sep 2022	292	9	0
Oct 2022	290	16	5
Nov 2022	206	7	2
Dec 2022	211	2	2
Jan 2023	252	13	6
Feb 2023	272	3	3
Mar 2023	180	3	0
Apr 2023	149	3	2
May 2023	140	1	0
Total	5000	185	95